Kristen Stewart Credit Suisse

Kristen Stewart, who repeats at No. 3, pays “great attention to both development pipelines and market sentiment,” observes one portfolio manager. Clients still applaud the Credit Suisse analyst’s November reiteration of her buy rating on Medtronic, which she made earlier — and at a lower price — than the analyst in first place. Stewart insisted that fears of the Minneapolis-based defibrillator maker’s earnings for the third quarter of its fiscal year, which ended January 29, being disastrous were overstated. She was right. The stock had advanced 7.2 percent, from $35.99 to $38.58, by mid-June, when Stewart discontinued coverage in anticipation of her move to Deutsche Bank Securities, which she joined in late July.